The Science of Peptide Cycling
Five days on, two days off. Eight weeks on, four weeks off. Most peptide cycling schedules are borrowed from one class of peptide and applied to another by analogy, not derived from the drug’s own pharmacology. Here is what the evidence actually establishes for BPC-157, the growth hormone secretagogues and the rest. It shows where loss of response is real and measurable, where a weekend off changes nothing, and where nobody has studied it.

Patients arrive with a schedule. Five days on, two days off. Eight weeks on, four weeks off. It came from a clinic, a forum, a coach, or a bottle insert, and it is usually delivered with confidence, as if the peptide needs a break or the receptors stop responding.
Some of that is sound pharmacology. Some of it is a calendar borrowed from one class of peptide and applied to another by analogy. The difference matters, because the peptides where a break has a genuine mechanistic rationale are not the ones most often cycled, and the peptide most often cycled has no identified receptor to reset.
Below is what the published evidence actually establishes, class by class, including where desensitization is real and measurable, where a weekend off is pharmacologically meaningless, and where the honest answer is that nobody has studied it. The short version is that the drug is better characterized than the schedule, and a schedule is a clinical decision rather than a rule of thumb.
1. Where the weekday-on, weekend-off rule came from
The Monday-to-Friday cadence is not derived from any peptide’s measured pharmacology. It is a convention carried over from how injectable hormones and growth hormone secretagogues have long been pulsed, then extended to whatever else is in the same syringe drawer. It also happens to be easy to remember, which is not a trivial advantage in a therapy that depends on adherence.
For the growth hormone axis, intermittent dosing has a real basis, because continuous receptor occupancy blunts the response and spacing doses preserves it. The error is generalization. Carrying that logic to a peptide with no known receptor, or to one with an eight-day half-life, produces a schedule that looks rigorous and changes almost nothing.
2. BPC-157 has rapid clearance and no receptor to reset
BPC-157 is the peptide most often prescribed on a cycled schedule and the one with the least justification for it. Plasma half-life in rats and dogs is under 30 minutes with linear, dose-proportional kinetics, and in the human intravenous pilot, plasma concentrations returned to baseline within 24 hours. Consecutive daily doses therefore do not stack up in the bloodstream. A single overnight interval already clears the compound, so a two-day gap is not a washout of anything that is still there.
The usual argument for cycling is receptor downregulation, and that argument does not apply here. BPC-157 has no identified single receptor and no reported tachyphylaxis. Its proposed actions are pleiotropic, running through VEGFR2 upregulation, Akt-eNOS and nitric oxide signaling, ERK1/2, and Egr-1 and TGF-beta effects on fibroblasts and collagen. There is no single switch for a weekend to flip back.
What the human record actually contains
Less than the schedules imply. All three human pilot studies used single administrations by routes that are not the ones clinics use. These included intravenous dosing (up to 20 mg in two healthy adults), a single 10 mg intravesical dose in twelve women with interstitial cystitis, and retrospective intra-articular knee injections in twelve patients. None of them gave a maintenance course, so there is no human dosing schedule to cite, cycled or continuous. Intramuscular data exist only in animals, where the ADME work measured bioavailability (roughly 14 to 19 percent in rats, 45 to 51 percent in dogs) rather than any on-off pattern.
This cuts both ways, and the honest statement is narrow. A need for cycling has not been demonstrated, and neither has the safety or superiority of uninterrupted dosing. Rapid clearance in animals does not establish repeated-dose human pharmacokinetics, absence of tolerance, or long-term safety. Reviews are explicit that indications, dosing, frequency, and duration remain uncharacterized.
The one reason a clinician may still build in breaks
The main theoretical concern with sustained exposure is angiogenic signaling through VEGF, which is relevant to cumulative exposure rather than to any single dose, and cumulative exposure is exactly what a dosing-frequency decision changes. The mechanistic picture is genuinely unsettled. The originating research group argues that BPC-157 modulates angiogenesis and nitric oxide signaling rather than pathologically driving it, and reports anti-tumor effects in animal models.
A clinician who limits total duration as a hedge is making a defensible judgment under uncertainty, not following evidence. That is a different thing from a weekend break, and it is a decision that belongs to someone who knows the patient’s history.
3. Where the growth hormone axis gives cycling a real rationale
For the secretagogues, intermittent exposure is not folklore. The relevant variable, though, is usually the spacing of doses within a day rather than a weekly calendar.
The GHRP class, including ipamorelin, GHRP-2, GHRP-6, and hexarelin
Desensitization in this class is documented and pattern-dependent. The classic human physiology showed partial desensitization, more during continuous infusion and less during intermittent administration. Animal work agrees. Three-hourly pulsatile ghrelin or GHRP-6 produced sustained growth hormone responses and skeletal growth, while continuous infusion produced a transient response with suppressed pulse amplitude. The mechanism was increased hypothalamic somatostatin tone rather than downregulation of the secretagogue receptor itself.
Dose spacing follows from that. More consistent responses were obtained with injections spaced to match the natural two-to-three-hour growth hormone pulse interval, while very frequent injections at 60 to 90 minutes produced cyclic, variable responsiveness. This is the basis for discrete injections separated by hours instead of continuous exposure. No trial has established an optimal number of doses per day, and none has established a required weekly break.
Human desensitization is also milder than cell and animal models suggest. A 34-hour continuous GHRP-6 infusion in healthy men preserved pituitary sensitivity, with sustained elevation of growth hormone pulse amplitude and IGF-1.
What hexarelin reversibility does and does not prove
Hexarelin is the one agent in this class with a long human dataset, and it is worth reading precisely. In healthy older adults given twice-daily injections for 16 weeks, the growth hormone response fell significantly by weeks 4 and 16, then returned to baseline four weeks after stopping. IGF-1, IGFBP-3, body composition, and bone density were essentially unchanged, so the measurable biological impact of that attenuation was small.
That establishes partial, reversible attenuation. It does not establish a recommended four-week holiday. The study did not test whether recovery happened sooner, whether a weekend break would have prevented the attenuation, or whether repeated cycles improved outcomes. Shorter intermittent courses by intranasal or oral routes over 8 to 15 days did not blunt the response at all, and nudged IGF-1 and IGFBP-3 upward.
A blunted test response is also not the same as a lost clinical effect. In short children on long-term intranasal hexarelin, pituitary responsiveness dropped after seven days while growth velocity still increased.
CJC-1295 has an eight-day half-life, making a weekend meaningless
The long-acting form is the clearest case of a schedule that does not match its drug. Half-life is roughly 5.8 to 8.1 days. A single dose raises growth hormone two- to tenfold for at least six days and IGF-1 for 9 to 11 days, and after multiple doses IGF-1 stays above baseline for up to 28 days. A two-day gap against an eight-day half-life changes cumulative exposure very little.
The concern here is not classic receptor tachyphylaxis but sustained, non-pulsatile stimulation. Single-injection data were reassuring on that point, showing preserved pulsatility with higher trough and mean growth hormone and unchanged pulse frequency and amplitude. Reviewers still warn that continuously elevated growth hormone can blunt the endogenous axis and bring insulin resistance, fluid retention, and organomegaly. With this drug, the levers that matter are dosing frequency across weeks and total duration of exposure, not a weekend off.
Sermorelin has a short half-life and is inherently pulsatile
Sermorelin is a growth hormone releasing hormone analog with a plasma half-life of roughly 10 to 20 minutes, so a daily subcutaneous dose clears quickly and leaves the body’s own pulsatile release and feedback intact. The class does desensitize under continuous exposure. Continuous infusion in normal men produced a diminished response to a subsequent challenge, while the pituitary stayed fully responsive to a different stimulus.
Sustained daily dosing, however, did not produce progressive tachyphylaxis in practice. Once-daily bedtime dosing sustained increased height velocity over 12 months, and up to 36 months in a few children, and six weeks of treatment in adults increased nocturnal growth hormone release and peak amplitude. The short half-life is what separates it from the long-acting analogs.
4. Half-life is not the duration of effect
Most cycling arguments quietly assume that a drug’s half-life tells you when its effect ends and when responsiveness returns. It does not. Half-life describes disappearance from blood. The pharmacokinetic and pharmacodynamic literature treats the gap between the two as the normal case, not the exception.
BPC-157 is the clearest example of the disconnect. Effects reportedly persist for hours to days despite clearance in under 30 minutes. Numbers also get quoted across contexts that are not interchangeable. The 55 minutes often attributed to hexarelin describes declining growth hormone concentrations, not measured clearance of the peptide. Animal estimates, human estimates, and different injection routes are three different things.
5. Where a dosing limit is genuinely on the label
Bremelanotide is the exception that shows what a validated limit looks like, and also what it is not. The label directs at least 24 hours between doses and does not recommend more than eight doses per month. Those limits exist for safety and for the extent of available experience, including blood pressure increases and hyperpigmentation. They are not a demonstrated receptor-reset interval, and melanocortin receptor desensitization shown in the laboratory does not supply a human recovery schedule.
The approved indication is also specific. It is acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is contraindicated in uncontrolled hypertension or known cardiovascular disease, so staying inside the dosing limits does not by itself establish that it is appropriate for a given person.
6. What is established, peptide by peptide
The table below separates three things that get blurred together. These are how fast the drug leaves the blood, whether loss of response has actually been measured in people, and whether any on-off schedule has been validated. Where the answer is that nobody has studied it, that is what it says.
| Peptide | How fast it clears | What is established about cycling |
| BPC-157 No single identified receptor | Under 30 min in rats and dogs, with no reliable human value | Loss of response was not studied, neither shown nor excluded. No validated cycle exists in either direction. |
| Thymosin beta-4 Actin-binding, not a classical receptor agonist | Dose-dependent after IV, with no reliable value for SC or IM | Loss of response was not studied adequately. No validated cycle exists. |
| Sermorelin GHRH receptor agonist | About 10 to 20 min | Loss of response showed the class desensitizes under continuous exposure, but daily dosing held up. No validated cycle exists, and no weekly reset has been demonstrated. |
| GHRP-2, GHRP-6, ipamorelin Ghrelin (GHS-R1a) agonists | Short, minutes to hours | Loss of response was partial and more pronounced with continuous exposure than with intermittent dosing. No validated cycle exists, though spacing within the day has support and a weekly calendar does not. |
| Hexarelin Ghrelin (GHS-R1a) agonist | No reliable human value. The quoted 55 min is falling GH, not the peptide. | Loss of response occurred, falling by weeks 4 and 16 and returning to baseline 4 weeks after stopping. No validated cycle exists, and reversibility at 4 weeks is not a required break. |
| CJC-1295 with DAC GHRH receptor agonist, long-acting | About 5.8 to 8.1 days, with IGF-1 raised 9 to 11 days by one dose | Loss of response was not seen after single doses, and pulsatility was preserved. The concern is continuous elevation. No validated cycle exists, and frequency and total duration are the levers, not a weekend. |
| Gonadorelin with testosterone therapy GnRH receptor agonist | About 2 to 6 min IV, and about 24 min SC in a small study | Loss of response occurred under sustained stimulation, though it is poorly characterized in this use. No validated cycle exists for this use, and pump dosing in fertility care is not the same thing. |
| Bremelanotide Melanocortin (MC4R, MC1R) agonist | Mean 2.7 hours after SC dosing | Loss of response from tolerance to the desired effect is not well characterized. No validated cycle exists, but the label limits exposure to at least 24 h apart and no more than 8 doses a month. |
| MOTS-c Mitochondrial peptide that binds and activates CK2 | No established human value for the native peptide | Loss of response was not studied adequately. No validated cycle exists. |
IV = intravenous, SC = subcutaneous, IM = intramuscular, GH = growth hormone, GHRH = growth hormone releasing hormone, GnRH = gonadotropin releasing hormone.
7. How a schedule should actually be set
None of this means peptide therapy is guesswork. It means the schedule is a clinical variable rather than a product feature, and the things that should drive it are known even where the calendar is not.
- Match the pattern to the pharmacology. For the GHRP class, spacing injections to respect the natural pulse interval is the part with mechanistic support. For a long-acting analog, frequency across weeks and total duration are what matter.
- Watch the response, not the calendar. Where desensitization is a real possibility, IGF-1 and symptom response over time are more informative than a preset break, and attenuation of a test response does not automatically mean the therapy has stopped working.
- Treat duration as the open question. For the peptides with no long-term human data, the defensible approach is a defined course with review rather than indefinite use by default.
- Know what is in the vial. With material from unregulated sources, identity, purity, and actual peptide content are unverified, which means a stated volume corresponds to an unknown delivered dose. Any discussion of precise scheduling is beside the point if the dose itself is unknown.
That last one is worth saying plainly, because it is the single biggest difference between a protocol that can be reasoned about and one that cannot. A schedule is only as meaningful as the dose it delivers.
The Verdict
A short half-life does not prove a peptide needs no breaks, and a known receptor does not prove that breaks help. Those are the two inferences nearly every cycling rule rests on, and neither holds on its own.
Where the evidence does point is consistent. For the growth hormone secretagogues, the anti-desensitization strategy with actual mechanistic support is intermittent rather than continuous exposure within the day, not any particular weekly on-off calendar. For the long-acting analogs, short breaks are pharmacologically irrelevant and cumulative duration is the real lever. For BPC-157 and the peptides like it, there is no receptor-reset logic to apply, no human repeated-dose data to appeal to, and no validated schedule in either direction.
So the useful conversation is not which calendar to copy. It is what is being treated, for how long, with what monitoring, from a source whose contents are verified. That is a decision to make with a clinician who can see the whole picture, and it is the part of a protocol that actually changes outcomes.
Key Takeaways
- The weekday-on, weekend-off rule is borrowed, not derived. It comes from how growth hormone secretagogues are pulsed and was extended by analogy to peptides with different pharmacology, including some with no identified receptor.
- Desensitization is real in the GHRP class, and depends on pattern. It is more pronounced with continuous exposure and less with intermittent dosing, driven by increased hypothalamic somatostatin tone rather than loss of the receptor itself.
- With a multi-day half-life, a weekend off does nothing. CJC-1295 with DAC elevates IGF-1 for 9 to 11 days after a single dose, so frequency across weeks and total duration are the only meaningful levers.
- BPC-157 clears fast, which settles less than it seems. No accumulation between daily doses, no documented tolerance, and also no human repeated-dose data, so neither cycling nor continuous use has been validated.
- Half-life is not duration of effect. Clearance from blood, persistence of a biological effect, and time to restored responsiveness are three different measurements, and quoted figures often describe a hormone response rather than the peptide.
- An unknown dose makes the schedule moot. Unverified identity and purity from unregulated sources mean a stated volume delivers an unknown amount, which matters more than any on-off pattern.
FAQ
My clinic has me on five days on, two days off. Is that wrong?
Not necessarily wrong, but for most peptides it is a convention rather than a finding. It is easy to follow and unlikely to cause harm. What it is not is a schedule derived from the peptide’s measured pharmacology, so it should not be defended as such, and it should not be copied from one peptide to another.
Does BPC-157 build up in my system if I take it every day?
No meaningful accumulation in blood would be expected, because clearance is rapid and a single overnight interval already clears it. That is an argument against needing a washout, not proof that continuous use is safe or better. Human repeated-dose data do not exist, which is why duration is worth revisiting with your clinician rather than left open-ended.
If I skip the break, will the peptide stop working?
For ipamorelin and the other ghrelin-receptor agonists, response can attenuate with sustained use, and in the longest human study it recovered within four weeks of stopping while IGF-1, body composition, and bone density stayed essentially unchanged. For the growth hormone releasing hormone analogs with short half-lives, daily dosing studies maintained the response. Monitoring tells you more than a preset break.
Does a weekend off protect me from side effects?
For a peptide with a half-life of days, the answer is no, because exposure barely changes. For the theoretical concerns that scale with cumulative exposure, total duration is what a clinician can actually adjust, which is a reason to agree on a defined course and a review date.
Is gonadorelin alongside testosterone keeping my fertility intact?
That has not been established. The fertility evidence for pulsatile GnRH comes from frequent, physiologic-frequency pump dosing in selected patients, not occasional injections added to testosterone, and gonadorelin is not interchangeable with hCG. Guidelines advise against exogenous testosterone for men who want fertility now or later, so if that matters to you it belongs in the conversation before starting, not after.
So are peptides worth it?
That depends on what you are treating and which peptide, and it is a different question from scheduling. What this review supports is modest and practical. Know the compound’s actual pharmacology, use a source whose contents are verified, set a duration with a review date, and measure what you can rather than following a calendar found online.
References
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Mayfield CK, Bolia IK, Feingold CL, et al. The American Journal of Sports Medicine. 2026;54(1):223-229. doi:10.1177/03635465251357593.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Mendias CL, Awan TM. Sports Medicine (Auckland, N.Z.). 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0.
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. Luansritisakul C, Chiang MC, Burns SL, Fonseca ACG. Current Pain and Headache Reports. 2026;30(1):109. doi:10.1007/s11916-026-01542-z.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625.
- Pharmacokinetics, Distribution, Metabolism, and Excretion of Body-Protective Compound 157, a Potential Drug for Treating Various Wounds, in Rats and Dogs. He L, Feng D, Guo H, et al. Frontiers in Pharmacology. 2022;13:1026182. doi:10.3389/fphar.2022.1026182.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025;31(5):20-24.
- BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals (Basel, Switzerland). 2025;18(10):1450. doi:10.3390/ph18101450.
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals (Basel, Switzerland). 2025;18(6):928. doi:10.3390/ph18060928.
- Protective Effects of BPC 157 in Rats With Experimentally Induced Lower Extremity Ischemia-Reperfusion Injury. Yıldırım AK, Demirtaş H, Özer A, Arslan M. Scientific Reports. 2026;16(1):24375. doi:10.1038/s41598-026-55449-1.
- The Emerging Landscape of Performance-Enhancing Peptides Modulating the GH-IGF1 Axis: Bridging the Gap Between Clinical Evidence and Patient Self-Administration. Dominikowski A, Rękoś Z, Olejarz M, et al. Frontiers in Endocrinology. 2026;17:1822475. doi:10.3389/fendo.2026.1822475.
- Is the Peptide Craze Backed by Science? The Promise Behind the Hype. Willyard C. Nature. 2026;654(8118):312-314. doi:10.1038/d41586-026-01816-x.
- Growth Hormone-Releasing Peptides. Ghigo E, Arvat E, Muccioli G, Camanni F. European Journal of Endocrinology. 1997;136(5):445-60. doi:10.1530/eje.0.1360445.
- Pattern-Dependent Suppression of Growth Hormone (GH) Pulsatility by Ghrelin and GH-Releasing Peptide-6 in Moderately GH-Deficient Rats. Thompson NM, Davies JS, Mode A, Houston PA, Wells T. Endocrinology. 2003;144(11):4859-67. doi:10.1210/en.2003-0423.
- Skeletal Growth Acceleration With Growth Hormone Secretagogues in Transgenic Growth Retarded Rats: Pattern-Dependent Effects and Mechanisms of Desensitization. Wells T, Houston PA. Journal of Neuroendocrinology. 2001;13(6):496-504. doi:10.1046/j.1365-2826.2001.00661.x.
- Consistent GH Responses to Repeated Injection of GH-Releasing Hexapeptide (GHRP-6) and the Non-Peptide GH Secretagogue, L-692,585. Fairhall KM, Mynett A, Smith RG, Robinson IC. The Journal of Endocrinology. 1995;145(3):417-26. doi:10.1677/joe.0.1450417.
- Effects of a Prolonged Growth Hormone (GH)-Releasing Peptide Infusion on Pulsatile GH Secretion in Normal Men. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. The Journal of Clinical Endocrinology and Metabolism. 1993;77(6):1641-7. doi:10.1210/jcem.77.6.7903313.
- Growth Hormone Status During Long-Term Hexarelin Therapy. Rahim A, O’Neill PA, Shalet SM. The Journal of Clinical Endocrinology and Metabolism. 1998;83(5):1644-9. doi:10.1210/jcem.83.5.4812.
- Does Desensitization to Hexarelin Occur? Rahim A, Shalet SM. Growth Hormone & IGF Research. 1998;8 Suppl B:141-3. doi:10.1016/s1096-6374(98)80039-7.
- Short-Term Administration of Intranasal or Oral Hexarelin, a Synthetic Hexapeptide, Does Not Desensitize the Growth Hormone Responsiveness in Human Aging. Ghigo E, Arvat E, Gianotti L, et al. European Journal of Endocrinology. 1996;135(4):407-12. doi:10.1530/eje.0.1350407.
- GH Responsiveness to Repeated GHRH or Hexarelin Administration in Normal Adults. Sartorio A, Conti A, Ferrero S, Spada A, Faglia G. Journal of Endocrinological Investigation. 1995;18(9):718-22. doi:10.1007/BF03349794.
- Desensitization From Long-Term Intranasal Treatment With Hexarelin Does Not Interfere With the Biological Effects of This Growth Hormone-Releasing Peptide in Short Children. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z. European Journal of Endocrinology. 1996;134(6):716-9. doi:10.1530/eje.0.1340716.
- Growth Hormone-Releasing Activity of Hexarelin in Humans: A Dose-Response Study. Imbimbo BP, Mant T, Edwards M, et al. European Journal of Clinical Pharmacology. 1994;46(5):421-5. doi:10.1007/BF00191904.
- Impact of Two or Three Daily Subcutaneous Injections of Hexarelin, a Synthetic Growth Hormone (GH) Secretagogue, on 24-H GH, Prolactin, Adrenocorticotropin and Cortisol Secretion in Humans. Maccario M, Veldhuis JD, Broglio F, et al. European Journal of Endocrinology. 2002;146(3):310-8. doi:10.1530/eje.0.1460310.
- Implications of Ghrelin and Hexarelin in Diabetes and Diabetes-Associated Heart Diseases. Mosa RM, Zhang Z, Shao R, et al. Endocrine. 2015;49(2):307-23. doi:10.1007/s12020-015-0531-z.
- Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Teichman SL, Neale A, Lawrence B, et al. The Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
- Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Ionescu M, Frohman LA. The Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702.
- Dual Effects of Growth Hormone (GH)-Releasing Hormone Infusion in Normal Men: Somatotroph Desensitization and Increase in Releasable GH. Vance ML, Kaiser DL, Rivier J, Vale W, Thorner MO. The Journal of Clinical Endocrinology and Metabolism. 1986;62(3):591-4. doi:10.1210/jcem-62-3-591.
- Treatment of Growth-Hormone Deficiency With Growth-Hormone-Releasing Hormone. Ross RJ, Rodda C, Tsagarakis S, et al. Lancet (London, England). 1987;1(8523):5-8. doi:10.1016/s0140-6736(87)90699-4.
- Once Daily Subcutaneous Growth Hormone-Releasing Hormone Therapy Accelerates Growth in Growth Hormone-Deficient Children During the First Year of Therapy. Thorner M, Rochiccioli P, Colle M, et al. The Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1189-96. doi:10.1210/jcem.81.3.8772599.
- Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children With Idiopathic Growth Hormone Deficiency. Prakash A, Goa KL. BioDrugs. 1999;12(2):139-57. doi:10.2165/00063030-199912020-00007.
- PEGylation of Growth Hormone-Releasing Hormone (GRF) Analogues. Esposito P, Barbero L, Caccia P, et al. Advanced Drug Delivery Reviews. 2003;55(10):1279-91. doi:10.1016/s0169-409x(03)00109-1.
- A Randomized, Placebo-Controlled, Single and Multiple Dose Study of Intravenous Thymosin Beta4 in Healthy Volunteers. Ruff D, Crockford D, Girardi G, Zhang Y. Annals of the New York Academy of Sciences. 2010;1194:223-9. doi:10.1111/j.1749-6632.2010.05474.x.
- Thymosin Beta4: Structure, Function, and Biological Properties Supporting Current and Future Clinical Applications. Crockford D, Turjman N, Allan C, Angel J. Annals of the New York Academy of Sciences. 2010;1194:179-89. doi:10.1111/j.1749-6632.2010.05492.x.
- Beta-Thymosins. Hannappel E. Annals of the New York Academy of Sciences. 2007;1112:21-37. doi:10.1196/annals.1415.018.
- Pharmacokinetics of Gonadotropin-Releasing Hormone: Comparison of Subcutaneous and Intravenous Routes. Handelsman DJ, Jansen RP, Boylan LM, Spaliviero JA, Turtle JR. The Journal of Clinical Endocrinology and Metabolism. 1984;59(4):739-46. doi:10.1210/jcem-59-4-739.
- Long-Term Administration of Gonadotropin-Releasing Hormone in Men With Idiopathic Hypogonadotropic Hypogonadism. Spratt DI, Finkelstein JS, O’Dea LS, et al. Annals of Internal Medicine. 1986;105(6):848-55. doi:10.7326/0003-4819-105-6-848.
- Gonadotropin-Releasing Hormone and Its Analogues. Conn PM, Crowley WF. The New England Journal of Medicine. 1991;324(2):93-103. doi:10.1056/NEJM199101103240205.
- Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; Amended 2024). American Urological Association. 2024.
- Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men With Testosterone-Induced Gonadotropin Suppression. Coviello AD, Matsumoto AM, Bremner WJ, et al. The Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2595-602. doi:10.1210/jc.2004-0802.
- Vyleesi (bremelanotide) prescribing information. U.S. Food and Drug Administration. Updated November 5, 2026.
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Simon JA, Kingsberg SA, Portman D, et al. Obstetrics and Gynecology. 2019;134(5):909-917. doi:10.1097/AOG.0000000000003514.
- Regulation of Melanocortin-4 Receptor Signaling: Agonist-Mediated Desensitization and Internalization. Shinyama H, Masuzaki H, Fang H, Flier JS. Endocrinology. 2003;144(4):1301-14. doi:10.1210/en.2002-220931.
- The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Lee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443-54. doi:10.1016/j.cmet.2015.02.009.
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008.
- MOTS-c Modulates Skeletal Muscle Function by Directly Binding and Activating CK2. Kumagai H, Kim SJ, Miller B, et al. iScience. 2024;27(11):111212. doi:10.1016/j.isci.2024.111212.
- All Half-Lives Are Wrong, but Some Half-Lives Are Useful. Wright JG, Boddy AV. Clinical Pharmacokinetics. 2001;40(4):237-44. doi:10.2165/00003088-200140040-00001.
- Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides. Diao L, Meibohm B. Clinical Pharmacokinetics. 2013;52(10):855-68. doi:10.1007/s40262-013-0079-0.


